Vegas wedding highlights growth urgency of generics companies
This article was originally published in Scrip
The soap opera-worthy saga of unrequited love featuring generics companies Teva, Mylan and Perrigo took a completely unexpected twist at the start of this week when Teva and Allergan agreed to get together. Teva is buying Allergan's generic pharmaceuticals business – the company formerly known as Actavis – for $40.5bn.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.